Compare Cytokinetics Inc (CYTK) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Solaredge Technologies Inc — how do they compare? Cytokinetics Inc trades at $73.05 (market cap $10.52B), while Solaredge Technologies Inc trades at $32.28 (market cap $1.97B). The key difference: Cytokinetics Inc is far larger — about 5.3× Solaredge Technologies Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | SEDG | |
|---|---|---|
Market Cap | $10.52B | $1.97B |
Sector | Technology | Technology |
52-Week High | $87.26 | $78.51 |
52-Week Low | $35.33 | $25.67 |
Enterprise Value | $10.62B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 1.06% with a bearish technical signal. The company shows strong commercial momentum with Myqorzo gaining traction internationally, but faces significant financial challenges including negative gross margin of -372.55% and net income margin of -1,321.12%. Recent Q2 2026 earnings beat revenue estimates despite posting losses, while regulatory approvals in the UK expand market access.
Investment outlook balances promising drug pipeline against substantial financial losses. Analyst consensus remains overwhelmingly bullish with 97% buy ratings and $111.14 price target, representing 47% upside potential. Key risks include high cash burn, competitive pressures, and the need for continued financing to support operations and drug development.
SolarEdge Technologies (SEDG) trades at $32.18, down 3.39% amid bearish technical signals and mixed earnings performance. The company reported a Q2 2026 EPS beat but faces negative profit margins and declining revenues from 2022 peaks. Recent news highlights execution risks and weak Q3 guidance, contributing to investor caution despite some positive analyst coverage.
The outlook remains challenging with persistent net losses and high dependency on policy incentives. Investment opportunities exist if margin recovery accelerates, but risks include U.S. residential market weakness and liquidity concerns. Wall Street sentiment is mixed with a $35.15 consensus target suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
